Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
Suboptimal exposure to antituberculosis (anti-TB) drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line anti-TB drug pharmacokinetics in children and adolescents at a global level. We systematically searched MEDLINE, Embase a...
Uložené v:
| Vydané v: | The European respiratory journal Ročník 61; číslo 3 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
01.03.2023
|
| Predmet: | |
| ISSN: | 1399-3003, 1399-3003 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Shrnutí: | Suboptimal exposure to antituberculosis (anti-TB) drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line anti-TB drug pharmacokinetics in children and adolescents at a global level.
We systematically searched MEDLINE, Embase and Web of Science (1990-2021) for pharmacokinetic studies of first-line anti-TB drugs in children and adolescents. Individual patient data were obtained from authors of eligible studies. Summary estimates of total/extrapolated area under the plasma concentration-time curve from 0 to 24 h post-dose (AUC
) and peak plasma concentration (
) were assessed with random-effects models, normalised with current World Health Organization-recommended paediatric doses. Determinants of AUC
and
were assessed with linear mixed-effects models.
Of 55 eligible studies, individual patient data were available for 39 (71%), including 1628 participants from 12 countries. Geometric means of steady-state AUC
were summarised for isoniazid (18.7 (95% CI 15.5-22.6) h·mg·L
), rifampicin (34.4 (95% CI 29.4-40.3) h·mg·L
), pyrazinamide (375.0 (95% CI 339.9-413.7) h·mg·L
) and ethambutol (8.0 (95% CI 6.4-10.0) h·mg·L
). Our multivariate models indicated that younger age (especially <2 years) and HIV-positive status were associated with lower AUC
for all first-line anti-TB drugs, while severe malnutrition was associated with lower AUC
for isoniazid and pyrazinamide.
-acetyltransferase 2 rapid acetylators had lower isoniazid AUC
and slow acetylators had higher isoniazid AUC
than intermediate acetylators. Determinants of
were generally similar to those for AUC
.
This study provides the most comprehensive estimates of plasma exposures to first-line anti-TB drugs in children and adolescents. Key determinants of drug exposures were identified. These may be relevant for population-specific dose adjustment or individualised therapeutic drug monitoring. |
|---|---|
| Bibliografia: | SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Undefined-1 ObjectType-Review-4 content type line 23 ObjectType-Article-3 |
| ISSN: | 1399-3003 1399-3003 |
| DOI: | 10.1183/13993003.01596-2022 |